Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (83)
- Scheduling (national classification system) (11)
- Manufacturing (10)
- Fees and payments (4)
- Safety monitoring and information (4)
- COVID-19 (3)
- Clinical trials (1)
- Import and export (1)
- Labelling and packaging (1)
- Legislation (1)
- Metal-on-metal hip replacement implants hub (1)
- Shortages and supply disruptions (1)
- Unique Device Identification (UDI) hub (1)
Search
202 result(s) found, displaying 26 to 50
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 March 2024
-
Meeting statementsRead the meeting statement from 10 October 2024 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Meeting statementsA meeting statement from the second meeting of the Point-of-care Manufacturing of Medical Devices Steering Committee is now available.
-
Scheduling decisions (final)This publication is a notice of decision made by a delegate of the Secretary of the Department of Health and Aged Care under regulation 42ZCZX of the Therapeutic Goods Regulations 1990, and the reasons for the decision.
-
Meeting statementsThe 80th meeting of the Advisory Committee on Medical Devices (ACMD), 8 August 2024.
-
Corporate reportsRead our business plan 2024-25 to find out about our strategic priorities and activities.
-
Corporate reportsDocuments released under the FOI Act in the 2023/24 financial year
-
Meeting statementsRead the meeting statement from 27 June 2024 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Corporate reportsThis Cost Recovery Implementation Statement (CRIS) 2024-2025 provides information on how we implement, and cost recover our regulatory activities.
-
Meeting statementsRead the meeting statement from 18 April 2024 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Meeting statementsA meeting statement from the first meeting of the Point-of-care Manufacturing of Medical Devices Steering Committee is now available.
-
Meeting statementsRead the meeting statement from 8 February 2024 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Meeting statementsRead the meeting statement from 7 December 2023 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Meeting statementsRead the meeting statement from 12 October 2023 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Corporate reportsThis guide applies to the manufacture of medicines, active pharmaceutical ingredients and sunscreens, unless exempt under provisions in the Therapeutic Goods Act 1989.
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 9 November 2023
-
Corporate reportsThis report provides information about our regulatory performance from 1 July 2022 to 30 June 2023.
-
Corporate reportsAccess our report on medical devices manufactured at the point-of-care - analysis of survey results by sector.
-
Corporate reportsRead our business plan 2023-24 to find out about our strategic priorities and activities.
-
Meeting statementsRead the meeting statement from 10 August 2023 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Corporate reportsDocuments released under the FOI Act in the 2022/23 financial year
-
Meeting statementsRead the meeting statement from 8 June 2023 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Corporate reportsThis Cost Recovery Implementation Statement provides information on how the TGA, within the Department of Health, implements and cost recovers its regulatory activities.
-
Meeting statementsMeeting statement from the Advisory Committee on Medical Devices (ACMD), 13 April 2023.
-
Corporate reportsThe Access Consortium is offering joint pipeline meetings to pharmaceutical and biotechnology companies.